GlassScriptPhysician profile
Prabhaker S Patel
NPI 1639242852
$24,800.26
in general payments reported to CMS, 2019-2025
37 companies · $2,863 in 2025
The $2,863 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,842 · 2020: $3,981 · 2021: $2,540 · 2022: $2,053 · 2023: $2,466 · 2024: $3,056 · 2025: $2,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,385.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $10,300.76 | 2019-2020 | |
| Abbvie INC. | $1,603.99 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,085.13 | 2019-2025 | Rexulti, Nuedexta, Abilify Mycite |
| Validus Pharmaceuticals LLC | $983.25 | 2019-2023 | Equetro |
| Supernus Pharmaceuticals, INC. | $948.79 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $872.43 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $824.05 | 2019-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $773.66 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $695.59 | 2019-2025 | Rexulti |
| Alkermes, INC. | $639.38 | 2022-2025 | Lybalvi, Aristada |
| Ironshore Pharmaceuticals INC. | $633.53 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $629.61 | 2022-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $597.71 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $527.62 | 2019-2025 | Trintellix |
| Bausch Health US, LLC | $484.64 | 2019-2025 | Aplenzin, Wellbutrin |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $428.72 | 2022-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $366.06 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $342.46 | 2019-2025 | Spravato, Invega |
| Neos Therapeutics, LP | $320.44 | 2021-2025 | Adzenys Xr-Odt |
| Corium, LLC | $284.16 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $234.84 | 2019-2022 | |
| Noven Therapeutics, LLC | $163.18 | 2022-2024 | Xelstrym |
| Avanir Pharmaceuticals, INC. | $158.97 | 2019-2022 | |
| Almatica Pharma LLC | $147.96 | 2022-2025 | Loreev Xr |
| Adlon Therapeutics L.P. | $113.36 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $110.51 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $90.39 | 2019-2020 | |
| Indivior INC. | $82.55 | 2019-2025 | Sublocade |
| Eisai INC. | $78.27 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $72.52 | 2022-2023 | Quviviq |
| Harmony Biosciences LLC | $53.96 | 2021-2023 | Wakix |
| Shire North American Group INC | $46.26 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $31.31 | 2024 | Lumryz |
| Jazz Pharmaceuticals INC. | $27.51 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $18.35 | 2023 | Horizant |
| Braeburn INC. | $15.37 | 2025 | Brixadi |
| Vertical Pharmaceuticals, LLC | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prabhaker Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.